Please login to the form below

Not currently logged in
Email:
Password:

Turnstone Biologics bolsters leadership team

Kris Elverum and José Otero join the group

Kris ElverumCanadian immuno-oncology company Turnstone Biologics has strengthened its leadership team with the addition of two new hires.

Kris Elverum (pictured right) joins as its chief business officer with more than 12 years’ experience in the pharmaceutical/biotech industry with expertise in corporate strategy, business development, commercial and operations.

Prior to his new role, he was chief business officer at SQZ Biotech, a clinical-stage group focusing on developing cell therapies.

He said: “I’m excited to join Turnstone at this clinical stage in the company’s growth.

“Oncolytic viruses and cancer vaccines have the potential to benefits a wide range of patients living with cancer, and the company’s proprietary viral platform technology is at the forefront of this emerging field.”

José OteroAdditionally, the company has also appointed José Otero (pictured left) as its vice president, manufacturing and CMC following 15 years experience in the biopharmaceutical industry, including bioprocess development, manufacturing, CMC of vaccines and biologics.

Otero joins from Seres Therapeutics, where he was vice president of bioprocess development and manufacturing.

Prior to his role at Seres, Otero served Merck & Co as its director of engineering.

Sammy Farah, chief executive officer, Turnstone Biologics, said: “The addition of industry veterans Kris and José further bolsters our leadership team and comes at a critical time for our company as we advance clinical development of our next-generation oncolytic viral immunotherapies.”

1st September 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics